Clinical Trials Browser

OTHER × Naltrexone × Genitourinary × Clear all

NCT07224009 2026-04-24

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT01650350 2022-03-04

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Phase 2 Terminated

7 enrolled 5 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Prostatic Neoplasms